Haematologica (May 2024)

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Alexey V. Danilov,
Ian W. Flinn,
Matthew S. Davids,
Beth Gregory,
Ohad Bentur,
David Sidransky,
Jennifer R. Brown

Affiliations

Alexey V. Danilov: City of Hope National Medical Center, Duarte, CA
Ian W. Flinn: Tennessee Oncology, Nashville, TN
Matthew S. Davids: CLL Center, Dana-Farber Cancer Institute, Boston, MA
Beth Gregory: Secura Bio, Inc., Las Vegas, NV
Ohad Bentur: Secura Bio, Inc., Las Vegas, NV
David Sidransky: Johns Hopkins University, Baltimore, MD
Jennifer R. Brown: CLL Center, Dana-Farber Cancer Institute, Boston, MA

DOI: https://doi.org/10.3324/haematol.2024.285043
Journal volume & issue: Vol. 999, no. 1

Abstract

Not available.

Published in Haematologica

ISSN: 0390-6078 (Print); 1592-8721 (Online)
Publisher: Ferrata Storti Foundation
Country of publisher: Italy
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: http://www.haematologica.org

About the journal